Vasopressin to Control Blood Loss during Hysterectomy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

• Published in: Journal of minimally invasive gynecology Vol. 29; no. 3; p. 355
• Main Authors: Hafidh, Bandr, Latifah, Hassan M, Gari, Abdulrahim, Alshahrani, Majed Saeed, AlSghan, Rayan, Alkhamis, Waleed H, Allam, Hassan Saleh, AlRasheed, May A, Bakhsh, Hanadi, Abu-Zaid, Ahmed, Baradwan, Saeed
• Format: Journal Article
• Language: English
• Published: United States 01.03.2022
• Subjects: Blood Loss, Surgical - prevention & control; Female; Humans; Hysterectomy - adverse effects; Hysterectomy - methods; Hysterectomy, Vaginal - adverse effects; Hysterectomy, Vaginal - methods; Randomized Controlled Trials as Topic; Vasopressins - therapeutic use; Hemoglobin; Febrile morbidity; Pelvic infection; Blood transfusion; Bleeding
• ISSN: 1553-4669
• DOI: 10.1016/j.jmig.2021.10.003

Minimizing intraoperative blood loss during hysterectomy is crucial to lessen associated perioperative morbidity. The aim of this investigation is to conduct a systematic review and meta-analysis of all randomized controlled trials (RCTs) that compared vasopressin versus normal saline in controlling intraoperative blood loss during hysterectomy. We screened 5 major databases (PubMed, Scopus, Web of Science, Embase, and the Cochrane Central Register of Controlled Trials) from inception till July 18, 2021. We used the following query search in all databases: (vasopressin OR arginine vasopressin OR argipressin OR antidiuretic hormone) AND (hysterectomy) AND (saline OR placebo OR control OR no treatment) AND (randomized OR randomised OR randomly). There was no language restriction during database screening. We considered all studies that met the following evidence-based criteria: (1) patients: individuals undergoing hysterectomy for any indication, (2) intervention: vasopressin, (3) comparator: normal saline, placebo, or no treatment, (4) outcomes: reliable extraction of any of our endpoints, and (5) study design: RCTs. We assessed risk of bias of included studies and pooled endpoints as mean difference (MD) or risk ratio (RR) with 95% confidence interval (CI). We performed statistical analysis using the Review Manager software, version 5.4.0. Seven RCTs with an overall low risk of bias met the inclusion criteria. This meta-analysis included a total of 455 patients; 232 and 223 patients were allocated to vasopressin and control group, respectively. The majority of RCTs were vaginal hysterectomy (n = 5), few abdominal hysterectomy, (n = 2) and no laparoscopic hysterectomy. The mean estimated intraoperative blood loss was significantly lower in favor of the vasopressin group compared with the control group (n = 6 RCTs, MD = -119.85 mL, 95% CI [-177.55, -62.14], p <.001). However, there was no significant difference between both groups regarding mean operating time, mean change in postoperative hemoglobin, mean hospital stay, rate of febrile morbidity, rate of pelvic infection, rate of perioperative blood transfusion, and rate of perioperative complications. Compared with normal saline, vasopressin significantly reduced the estimated blood loss during hysterectomy but did not change any clinically significant outcomes. In addition, vasopressin was safe and did not correlate with an increase in the rates of febrile morbidity or pelvic infection.